Division of Molecular Pathology, The Institute of Cancer Research, London, UK; Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK.
Division of Radiotherapy and Imaging, Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, London, UK.
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188520. doi: 10.1016/j.bbcan.2021.188520. Epub 2021 Feb 6.
The field of immuno-oncology has expanded rapidly over the past decade, but key questions remain. How does tumour-immune interaction regulate disease progression? How can we prospectively identify patients who will benefit from immunotherapy? Identifying measurable features of the tumour immune-microenvironment which have prognostic or predictive value will be key to making meaningful gains in these areas. Recent developments in deep learning enable big-data analysis of pathological samples. Digital approaches allow data to be acquired, integrated and analysed far beyond what is possible with conventional techniques, and to do so efficiently and at scale. This has the potential to reshape what can be achieved in terms of volume, precision and reliability of output, enabling data for large cohorts to be summarised and compared. This review examines applications of artificial intelligence (AI) to important questions in immuno-oncology (IO). We discuss general considerations that need to be taken into account before AI can be applied in any clinical setting. We describe AI methods that have been applied to the field of IO to date and present several examples of their use.
免疫肿瘤学领域在过去十年中迅速发展,但仍存在一些关键问题。肿瘤与免疫的相互作用如何调节疾病进展?我们如何前瞻性地识别将从免疫治疗中获益的患者?确定具有预后或预测价值的肿瘤免疫微环境的可测量特征将是在这些领域取得有意义进展的关键。深度学习的最新发展使得对病理样本进行大数据分析成为可能。数字化方法允许对数据进行采集、整合和分析,这远远超出了传统技术的能力范围,而且效率高、规模大。这有可能重塑在数量、精度和输出可靠性方面所能取得的成果,使大样本量的数据能够得到总结和比较。这篇综述探讨了人工智能(AI)在免疫肿瘤学(IO)重要问题中的应用。我们讨论了在任何临床环境中应用 AI 之前需要考虑的一般注意事项。我们描述了迄今为止应用于 IO 领域的 AI 方法,并展示了它们的几个应用实例。